Janney Montgomery Scott LLC Grows Stake in Abbott Laboratories $ABT

Janney Montgomery Scott LLC raised its holdings in Abbott Laboratories (NYSE:ABT) by 3.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 688,971 shares of the healthcare product maker’s stock after buying an additional 23,827 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Abbott Laboratories were worth $62,517,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the 4th quarter worth $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth about $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT opened at $116.12 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock has a market cap of $200.94 billion, a P/E ratio of 37.58, a P/E/G ratio of 2.26 and a beta of 0.59. The business’s 50 day moving average price is $101.15 and its 200-day moving average price is $100.09. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the company earned $1.26 EPS. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s payout ratio is presently 81.55%.

Analysts Set New Price Targets

A number of research firms have weighed in on ABT. Citigroup upped their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. TD Cowen raised their target price on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday. The Goldman Sachs Group reduced their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Finally, Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first continuous monitor designed to track both glucose and ketone levels. The device could strengthen Abbott’s FreeStyle Libre ecosystem, help identify rising ketones before diabetic ketoacidosis emergencies, and support compatibility with automated insulin-delivery systems. Reuters article
• Positive Sentiment: TD Cowen raised its price target for ABT to $135 from $115 and maintained a “buy” rating. The upgrade signals confidence in Abbott’s growth prospects, particularly in continuous glucose monitoring and medical devices. Benzinga article
• Positive Sentiment: Medtronic’s MiniMed Flex insulin pump has begun shipping with an Abbott-made glucose sensor, expanding the potential distribution and application of Abbott’s sensor technology in automated insulin delivery. MedTech Dive article
• Neutral Sentiment: Recent comparisons portray Abbott as a relatively attractive healthcare and continuous glucose monitoring investment, citing valuation, liquidity and price-target upside. These assessments may support sentiment but do not represent new company operating results. Yahoo Finance article
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formulas contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Insider Monkey article
• Negative Sentiment: Diagnostics growth remains uneven: strong routine testing and 13% cancer-diagnostics growth are being partly offset by weaker respiratory testing demand. This could temper near-term revenue momentum. Yahoo Finance article

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.